Analyst consensus rating
Eli Lilly and Analyst Rating: Buy
Direct answer
Eli Lilly and's consensus rating is Buy.
30 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $1,333.72.
Forecast evidence checked October 27, 2026.
Get free Eli Lilly and email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1,281.91
- Average price target
- $1,333.72
- High price target
- $1,600.00
- Low price target
- $930.00
- Low target gap
- -27.5%
- Target upside
- +4%
- High target gap
- +24.8%
- Target range width
- 52.3%
- Consensus rating
- Buy
- Analysts
- 30
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Eli Lilly and?
Eli Lilly and has a verified Buy consensus. The same dataset has an average price target of $1,333.72.
How far are Eli Lilly and's low and high targets from the recorded price?
The low target implies -27.5%, while the high target implies +24.8%.
How many analysts are included in Eli Lilly and's consensus?
The verified consensus includes 30 analysts.
How is Eli Lilly and's target upside or downside calculated?
The average target of $1,333.72 is divided by the recorded price of $1,281.91, then one is subtracted to produce +4%. This does not guarantee a future return.
When was Eli Lilly and's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.